The CDK12 mutation, even though has low fractions in all the three groups (0% in CP, 2.8% in bone-MFP, and 5.9% in liver-MFP), has also been demonstrated to increase genomic instability58 and aggressiveness59 in prostate cancer. This evidence concerns the gene CDK12 and prostate cancer.